Foundation Medicine

Foundation Medicine
Name	Foundation Medicine
Type	Subsidiary
Industry	Biotechnology
Founded	2010
Founders	Ken Dorsheimer, Cyrus Massoud, Elisabeth Iorns
Headquarters	Cambridge, Massachusetts
Parent	Roche

Foundation Medicine is a biotechnology company specializing in genomic profiling and molecular diagnostics for oncology. The company developed comprehensive genomic profiling assays used to detect actionable genomic alterations in solid tumors, hematologic malignancies, and rare cancers, integrating next-generation sequencing with bioinformatics. Foundation Medicine's work intersects with precision oncology initiatives, companion diagnostics programs, and large-scale genomic databases.

History

Foundation Medicine was founded in 2010 in Cambridge, Massachusetts amidgrowth in precision medicine and follow-on developments from projects like the Human Genome Project, the Cancer Genome Atlas and initiatives led by institutions such as Broad Institute and Dana-Farber Cancer Institute. Early leadership engaged collaborations with academic centers including Massachusetts General Hospital and Memorial Sloan Kettering Cancer Center. The company launched its first clinical offering as genomics technology matured alongside regulators such as the U.S. Food and Drug Administration and reimbursement policies influenced by agencies like the Centers for Medicare & Medicaid Services. Acquisition by Roche integrated Foundation's assays into a global diagnostics and pharmaceutical portfolio alongside subsidiaries such as Genentech and complements companion diagnostic pathways established with partners including Pfizer, AstraZeneca, and Novartis. Foundation Medicine expanded operations through partnerships with cancer centers like MD Anderson Cancer Center, multi-site consortia including Lung Cancer Mutation Consortium, and translational research programs affiliated with University of California, San Francisco and Johns Hopkins University.

Products and Services

Foundation Medicine commercialized a suite of assays and services for oncologists and researchers. Key products included comprehensive genomic profiling assays tailored for solid tumors and hematologic malignancies, and tumor profiling reports designed to inform targeted therapies from companies such as AstraZeneca and Merck & Co.. Services addressed diagnostic workflows in settings tied to institutions like Mayo Clinic and networks such as Commission on Cancer. Foundation's offerings interfaced with clinical trial matching platforms run by organizations like National Cancer Institute and industry-sponsored studies from firms such as Bristol-Myers Squibb and Eli Lilly and Company. The company also provided data analytics and real-world evidence services leveraging data repositories reminiscent of efforts at European Molecular Biology Laboratory and initiatives like Project GENIE.

Technology and Methodology

Foundation Medicine's methodology combined next-generation sequencing platforms like those developed by Illumina with proprietary bioinformatics pipelines influenced by algorithms from groups at Broad Institute and MIT. The assays detected base substitutions, indels, copy number alterations, and select gene rearrangements across panels of cancer-related genes, drawing interpretive frameworks comparable to guidelines from American Society of Clinical Oncology and College of American Pathologists. Laboratory processes adhered to standards exemplified by certifications such as Clinical Laboratory Improvement Amendments and accreditations parallel to College of American Pathologists checklists. Analytical validation approached metrics used in landmark studies published in journals like The New England Journal of Medicine and Nature Medicine. The company integrated annotation frameworks akin to those from COSMIC and data-sharing models similar to GenBank for variant curation and interpretation.

Clinical Applications and Impact

Clinicians used Foundation Medicine reports to inform targeted therapy selection in disease areas exemplified by non-small-cell lung carcinoma, breast cancer, colorectal cancer, and rare tumor types treated at centers such as Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center. The assays supported enrollment into precision trials like those coordinated by National Cancer Institute and registry studies run by European Society for Medical Oncology. Impact assessments referenced outcome measures commonly used in trials by American Society of Clinical Oncology and health technology assessments conducted by agencies such as Institute for Clinical and Economic Review. Foundation's data contributed to biomarker discovery efforts that paralleled work in programs like Stand Up To Cancer and translational research consortia at Dana-Farber Cancer Institute.

Partnerships and Collaborations

Foundation Medicine formed strategic collaborations across industry, academia, and non-profit sectors. Industry partners included pharmaceutical companies like Roche, Pfizer, Novartis, AstraZeneca, Merck & Co., and Bristol-Myers Squibb for co-development of companion diagnostics and enrichment strategies for trials. Academic collaborations involved institutions such as Dana-Farber Cancer Institute, Johns Hopkins University, University of California, San Francisco, Memorial Sloan Kettering Cancer Center, MD Anderson Cancer Center, and Broad Institute. The company engaged with consortia and initiatives like The Cancer Genome Atlas, Project GENIE, Lung Cancer Mutation Consortium, and registries maintained by National Cancer Institute and European Society for Medical Oncology. Partnerships extended to diagnostic and platform companies including Illumina and health informatics collaborators aligned with Epic Systems Corporation and clinical trial networks such as SWOG.

Regulation and Reimbursement

Regulatory interfaces for Foundation Medicine involved agencies such as the U.S. Food and Drug Administration and international regulators like the European Medicines Agency for use of assays as companion diagnostics in approvals of therapeutics from firms like Genentech and AstraZeneca. Laboratory accreditation and practice standards referenced Clinical Laboratory Improvement Amendments and professional guidance from College of American Pathologists and American Society of Clinical Oncology. Reimbursement dynamics intersected with payers and policies shaped by Centers for Medicare & Medicaid Services and private insurers whose coverage determinations influenced clinical adoption at centers like Mayo Clinic and networks including Commission on Cancer. Health technology assessments by organizations such as Institute for Clinical and Economic Review informed cost-effectiveness discussions relevant to precision oncology testing.

Category:Biotechnology companies